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Abstract Thyroid hormones (T3, T4) are well known
modulators of different cellular signals including the
sphingomyelin pathway. However, studies regarding
downstream effects of T3 on sphingolipid metabolism in
skeletal muscle are scarce. In the present work we sought
to investigate the effects of hyperthyroidism on the activity
of the key enzymes of ceramide metabolism as well as
the content of fundamental sphingolipids. Based on fiber/
metabolic differences, we chose three different skeletal
muscles, with diverse fiber compositions: soleus (slow-
twitch oxidative), red (fast-twitch oxidative-glycolytic)
and white (fast-twitch glycolytic) section of gastrocne-
mius. We demonstrated that T3 induced accumulation of
sphinganine, ceramide, sphingosine, as well as sphingo-
myelin, mostly in soleus and in red, but not white section
of gastrocnemius. Concomitantly, the activity of serine
palmitoyltransferase and acid/neutral ceramidase was
increased in more oxidative muscles. In conclusion,
hyperthyroidism induced fiber specific changes in the
content of sphingolipids that were relatively more related
to de novo synthesis of ceramide rather than to its gen-
eration via hydrolysis of sphingomyelin.















THR Thyroid hormone receptor
Introduction
Thyroid hormones (T3, T4) are well known modulators of
whole body energy utilization. However, they also serve as
an important molecular signaling transducers [1]. A num-
ber of cellular signaling pathways are modified by triio-
dothyronine (T3), including the sphingomyelin/ceramide
pathway [2]. Skeletal muscles constitute the bulk of the
body’s total metabolic activity either by virtue of its mass
or oxidative capacity, and thus represent an important
target for the action of T3 [3]. Furthermore, others indicate
high expression of T3 receptor (THR) in muscle fibers [4]
and interestingly, the thyroid hormone receptors density is
muscle specific as slow-twitch (oxidative) fibers are more
sensitive to T3 than fast-twitch (glycolytic) muscles [5].
Recently, diminished content of ceramide with a con-
comitant increase in sphingomyelin concentration, in
skeletal muscles was reported in hypothyroid rats [6].
Ceramide content in myocytes is a net result of myocellular
ceramide generation (by hydrolysis of sphingomyelin or de
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novo synthesis pathway) and its degradation (by ceramid-
ases) [7]. The formation of ceramide de novo begins with
condensation of serine and palmitoyl-CoA, the reaction
catalyzed by serine palmitoyltransferase (SPT). However,
hydrolysis of sphingomyelin, can also generate substantial
amounts of ceramide, through the increased activity of
specific sphingomyelinases (acidic and/or neutral sphing-
omyelinases—aSM-ase/nSM-ase). In contrast, degradation
of ceramide occurs mainly by its deacylation and formation
of sphingosine in a reaction catalyzed by specific ceram-
idases (CDase, acidic, neutral and alkaline). Sphingosine
might also be further phosphorylated to sphingosine-1
phosphate. In addition, it should be noted that most of the
steps involved in sphingolipid metabolism is reversible [8].
Increasing evidence strongly supports involvement of dif-
ferent sphingolipids in the regulation of myocellular
functions [9, 10], and disturbances in sphingolipid forma-
tion have been found essential in the induction of pathol-
ogies [2]. More specifically, elevated concentrations of
ceramide or other sphingolipid intermediates are impli-
cated in the induction of insulin resistance in skeletal
muscle [8]. However, after exercise (a known insulin-
sensitizing effect), higher ceramide content was also
reported in muscles, in animals [11] and humans [12].
At present, it is unclear whether thyroid hormones
influence sphingolipid metabolism in skeletal muscles.
Therefore, the activity of key enzymes of ceramide
metabolism (serine palmitoyltransferase, neutral sphingo-
myelinase, acid sphingomyelinase, neutral ceramidase and
alkaline ceramidase) as well as the content of sphingolipid
metabolism products (sphingosine, sphinganine, sphingo-
sine-1-phosphate, ceramide and sphingomyelin) were
measured. To investigate the effects of hyperthyroidism,
rats were made hyperthyroid (n = 8) over 10 days using T3
i.p. injections and subsequently three types of skeletal
muscles were taken: soleus (slow-twitch oxidative), red
(fast-twitch oxidative-glycolytic) and white (fast-twitch
glycolytic) section of gastrocnemius.
Materials and Methods
The experimental protocol was approved by the Ethical
Committee for Animal Experiments at the Medical Uni-
versity of Białystok. Male Wistar rats (200–220 g body
weight) were housed under controlled conditions
(21 C ± 2, 12 h light/12 h dark cycle) with unlimited
access to standard chow and water. The animals were
divided into two groups, control (n = 8) and treated with
triiodothyronine (T3) (n = 8). Triiodothyronine (Sigma–
Aldrich, St. Louis, MO) was injected subcutaneously with
a dose of 100 lg/100 g of body weight, daily for 10 days
[13]. This dose is quite commonly used to mimic
hyperthyroidism in humans [13, 14]. Control rats were
treated with saline accordingly. After 10 days, rats were
fasted overnight and anaesthetized by intraperitoneal
injection of pentobarbital with a dose of 80 mg/kg of body
weight. Fasting blood samples were collected sodium-
heparinized tubes and centrifuged at 20,0009g for 20 min
at 4 C. Plasma was removed and stored at -80 C until
analyzed. Concomitantly, the soleus, red and white section
of gastrocnemius were excised, cleaned of blood and/or
connective tissue and immediately frozen in liquid nitrogen
and then stored at -80 C until analysis.
Sphingomyelin Content
The tissue samples were pulverized in an aluminum mortar
precooled previously in liquid nitrogen. The powder was
then transferred to a tube which contained methanol and
0.01 % butylated hydroxytoluene (Sigma) as an antioxidant.
Lipids were extracted by the method described by Bligh
and Dyer [15]. Then the lipid samples were spotted on
thin-layer chromatography (TLC) silica plates (Kieselgel
60, 0.22 mm, Merck) and developed as described by Maha-
devappa et al. [16]. Standards of sphingomyelin (Sigma)
were run along with the samples. Lipid bands were visual-
ized under ultraviolet light after spraying with a 0.5 %
solution of 3070-dichlorofluorescein in absolute methanol.
The gel bands corresponding to the sphingomyelin were
scraped off the plate and transferred into screw tubes con-
taining pentadecanoic acid (Sigma–Aldrich, St. Louis, MO)
as an internal standard. Sphingomyelin fatty acids were then
transmethylated and subsequently analyzed by means of
gas–liquid chromatography. A Hewlett-Packard 5890 Series
II system, equipped with a double flame ionization detector
and Agilent CP-Sil 88 capillary column (100 m, internal
diameter of 0.25 mm), was used. The sphingomyelin content
is presented as the sum of individual fatty acid residues.
Ceramide Content
A small (50 ll) volume of the chloroform phase, contain-
ing the lipids extract was transferred to a fresh tube which
contained an internal standard (C17-sphingosine, Avanti
Polar Lipids, UK). Ceramide (Cer) present in the organic
phase was hydrolyzed in 1 M KOH in 90 % methanol at
90 C for 60 min. This digestion procedure does not con-
vert complex sphingolipids, such as SM, galactosylcera-
mide, or glucosylceramide, into free sphingoid bases [17].
The content of free sphingosine, liberated from Cer was
next analyzed by means of HPLC (Varian Inc. OmniSpher
5, 4.6 9 150 mm). The calibration curve was prepared
using N-palmitoylsphingosine (Avanti Polar Lipids, UK) as
a standard. The chloroform extract used for the analysis of
Cer level also contains small amounts of free sphingoid
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bases. Therefore, the content of Cer was corrected for the
level of free sphingosine determined in the same sample.
Sphingosine, Sphinganine and Sphingosine-1-
Phosphate Content
The ceramide derivatives were measured according to the
method, described by Min et al. [18]. Prior to sample
homogenization and ultrasonication, internal standards
(C17-sphingosine and C17-S1P, Avanti Polar Lipids, Ala-
baster, AL) were added. The sphingoid bases were con-
verted to their o-phthalaldehyde derivatives and analyzed
on a HPLC system (ProStar, Varian, Inc., Palo Alto, CA)
equipped with a fluorescence detector and C18 reversed-
phase column (Varian, Inc., OmniSpher 5, 4.6 9 150 mm).
The Activity of SPT Neutral SMase and Acid SMase
The protein content was measured in all homogenates prior
to enzymatic analysis with the BSA protein assay kit
(Sigma–Aldrich, St. Louis, MO). As a standard, bovine
serum albumin (fatty acid free, Sigma–Aldrich, St. Louis,
MO) was used.
The activity of SPT, neutral and acid isoforms of
sphingomyelinase was determined accordingly [11, 19],
with the use of radiolabeled substrate (Perkin-Elmer Life
Sciences, Waltham, MA). The product of reaction 14C-
choline phosphate or 3H-L-serine was extracted with
CHCl3/methanol (2, 1, v/v), transferred to scintillation
vials, and counted using a Packard TRI-CARB 1900 TR
scintillation counter.
The Activity of Alkaline (alCDase) Ceramidase
and Neutral (nCDase) Ceramidase
The activity of neutral CDase and alkaline CDase was
measured by the method described by Nikolova-Karak-
ashian et al. [20]. The activity was determined with the use
of radiolabeled [N-palmitoyl-1-14C]-sphingosine (Moravek
Biochemicals, Brea, CA) as a substrate. Unreacted cera-
mide and liberated 1-14C-palmitate were separated with the
basic Dole solution (isopropanol/heptane/1 N NaOH, 40,
10, 1, v/v/v). Radioactivity of the 1-14C-palmitate was
measured by scintillation counting.
THR Expression
The protein expression of THRa, b-actin (50 lg) was
determined in muscle homogenates. The routine Western
blotting technique was used to detect the protein content.
Briefly, the total protein content in each sample was
determined by BCA (bicinchoninic acid) method. Then, the
proteins in each sample were separated using 10 %
SDS–polyacrylamide gel electrophoresis and transferred
to the nitrocellulose membrane. Equal protein concentra-
tions were loaded in each lane as confirmed by Ponceau
staining the blot membrane. In the next step, membranes
were immunoblotted with selected primary antibodies
(THRa, b-actin (Abcam, EU). Quantification of the selected
protein content was achieved by densitometry (OD-Optical
Density; Biorad, Poland). The THRa expression was related
to b-actin and then to the control that was set to 100 %.
Plasma FFA and Triiodothyronine (T3) Concentration
To measure the content of plasma FFA, lipids were
extracted from the plasma samples and subsequently the
fraction of FFA was isolated by means of TLC (Merck,
Germany). The gel bands, corresponding to the FFA
standard, were scraped off the plates and transferred into
fresh tubes. FFAs were then transmethylated with BF3/
methanol and the content of their methyl esters was
determined by means of gas–liquid chromatography (GLC)
[21]. The total content of plasma FFA was estimated as the
sum of the particular fatty acid species and was expressed
in nanomoles per milliliter of the plasma. T3 concentration
was measured in serum, with a commercially available kit,
according to manufacture instruction (Rat Tri-iodothyro-
nine, T3 ELISA kit, EIAab).
Statistical Analysis
Data are presented as means ± SE. Statistical significance
was assessed using two-way ANOVA followed by the
Newman–Keuls post hoc test. Differences were considered
significant at p \ 0.05.
Results
Effects of T3 Treatment on the Plasma T3
Concentration and Muscle THR Expression
Prior to the sphingolipids examination, we verified the
effects of prolonged (10 days) T3 i.p. administration on
plasma T3 concentration and thyroid hormone receptor
expression in muscles examined. We found a significant
increase in plasma T3 (Fig. 1a, ?5.0-fold, p \ 0.05), which
resulted in downregulation of the THR expression (Fig. 1c,
-21 %, -25 %, p \ 0.05 and -11 %, p [ 0,05). Fur-
thermore, plasma FFA content was significantly increased
along with T3 administration (Fig. 1b, ?4.8-fold,
p \ 0.05).
Lipids (2013) 48:697–704 699
123
Effects of T3 Treatment on the Sphingolipids Content
Prolonged high levels of serum T3 influenced sphingolipids
metabolism in skeletal muscles. We noticed an increased
content of sphinganine (an important substrate for de novo
synthesis of ceramide), that was significantly higher in
more oxidative muscles of hyperthroids rats, namely
in soleus and in the red section of gastrocnemius (Fig. 2a,
4.2-fold and 2.2-fold, p \ 0.05, respectively). Subse-
quently, we observed significant elevation of the content of
ceramide in soleus and red gastrocnemius (Fig. 2b, ?22
and ?21 %, p \ 0.05, respectively), accompanied by a
significant increase in sphingosine content (Fig. 2c, ?65
and ?53 %, p \ 0.05, respectively). In contrast, hyper-
thyroidism had no significant effects on sphingosine-
1-phosphate content in the muscles studied (Fig. 2d),
although a trend towards an increase in S1P was noticed in
soleus (p = 0.064). Hyperthyreosis induced enhancements
in the content of sphingomyelin in both soleus and red
gastrocnemius (Fig. 2e, ?45 % and ?41 %, p \ 0.05,
respectively) with modest effects on sphingomyelin con-
centration in white gastrocnemius.
Effects of T3 Treatment on the Activity of Key
Enzymes Involved in Sphingolipid Metabolism
T3 treatment had only a minor effect on the activity of either
neutral or acid sphingomyelinases in each muscle studied
(Fig. 3a, b). Correspondingly, prolonged T3 treatment did
not induce significant changes in the activity of neutral
ceramidase in red and white gastrocnemius (Fig. 3c,
p [ 0.05), but increased activity in soleus (Fig. 3c, 45 %,
p \ 0.05). Furthermore, hyperthyreosis induced enhance-
ments in the activity of alkaline ceramidase in soleus
(Fig. 3d, ?110 %, p \ 0.05), but not in gastrocnemius
(Fig. 3d, p [ 0.05). In hyperthyroid rats the activity of
serine palmitoyltransferase was significantly greater in

















































































Fig. 1 Effects of T3 treatment
(10 days) on the concentration
of plasma T3 (a), FFA (b) and
THRa expression (c) (Western
blot) in muscle homogenates.
RG, red section of the
gastrocnemius; WG, white
section of the gastrocnemius;
T3, triiodothyronine; THRa,
thyroid hormone receptor alpha.
Results are based on eight
independent preparations for
each experimental treatment
(mean ± SE). *p \ 0.05,
control vs treatment (T3)
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?70 %, ?58 %, p \ 0.05) and only a trend was observed in
white gastrocnemius (Fig. 3e, ?48 %, p = 0.07).
Discussion
The present study examined the effects of hyperthy-
roidism on sphingolipid metabolism in three different
types of skeletal muscles. We have demonstrated that
prolonged, in vivo, T3 administration increased the
content of both sphinganine, ceramide, and sphingosine
in soleus and red gastrocnemius, but not in the white
portion of gastrocnemius muscle. Accordingly, in these
muscles, the enhancement in sphingolipid content was
accompanied by a greater activity of serine palmitoyl-
transferase (SPT) and, to a lesser extent ceramidases (n-
CDase, al-CDase). This indicates that hyperthyroidism
accelerates sphingolipid metabolism in a fiber-specific
manner, mainly via increased de novo ceramide
synthesis.
Fig. 2 Effects of in vivo T3 administration (10 days) on the content
of: sphinganine (a), ceramide (b), sphingosine (c), sphingosine-1-
phosphate (d) and sphingomyelin (e) in rat skeletal muscles. RG, red
section of the gastrocnemius; WG, white section of the
gastrocnemius; T3, triiodothyronine. Results are based on eight
independent preparations for each experimental treatment
(mean ± SE). *p \ 0.05, control vs treatment (T3)
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It is well known, that triiodothyronine (T3) exerts pro-
nounced effects on body metabolism, affecting not only
energy utilization, but also major cellular signaling path-
ways [5], including the sphingomyelin pathway [1, 22]. In
addition, molecular actions of T3 (via activation of its
receptors) in skeletal muscles, are fiber specific [4, 23].
Recent data point to a greater responsiveness for T3 treat-
ment in soleus muscle (slow-twitch oxidative fibers) than
in plantaris (fast-twitch oxidative-glycolytic mixed mus-
cle). This greater response was mainly due to the increased
peroxisome proliferator activated receptor coactivator 1a
(PGC-1a) expression, followed by increased size and
number of mitochondria in soleus but not in plantaris
muscle [3, 24]. The aforementioned study probably
explains T3-induced increased rates of fatty acid metabo-






































































































Fig. 3 Effects of in vivo T3 administration (10 days) on the activity
of neutral sphingomyelinase (a), acid sphingomyelinase (b), neutral
ceramidase (c), alkaline ceramidase (d), serine palmitoyltransferase
(e) in rat skeletal muscles. RG, red section of the gastrocnemius; WG,
white section of the gastrocnemius; T3, triiodothyronine. Results are
based on eight independent preparations for each experimental
treatment (mean ± SE). *p \ 0.05, control vs treatment (T3)
702 Lipids (2013) 48:697–704
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muscles. Furthermore, it is well established, that triiodo-
thyronine can regulate muscle metabolism via multiple
molecular mechanism, including direct AMPK activation
[25] or through elevated calcium levels and CaMKKb
activation [26]. Hyperthyroidism induced AMPK activa-
tion substantially increased substrate metabolism in heart
[27] as well as in skeletal muscle [28]. However, there are
only a few studies addressing the influence of AMPK
activation on the activity of enzymes involved in ceramide
metabolism [29, 30] and it is still unclear whether
increased rates of palmitate metabolism are directly related
to the rates of ceramide metabolism. Indirect evidence is
provided by studies showing increased ceramide content in
skeletal muscles after exercise during which AMPK is
activated [11, 12]. Presumably, greater rates of fatty acid
utilization, along with a higher content of neutral lipids
(such as triacylglycerols) [31] may result in faster rates of
ceramide metabolism in more oxidative muscles. Accord-
ingly, in the present study as well as in previous reports
[32], higher concentrations of ceramide and other sphin-
golipids in these muscles were noticed. Also, along with
greater content of ceramide, we observed increased activity
of the key enzymes involved in sphigolipids metabolism in
more oxidative fibers. Furthermore, it seems that different
skeletal muscles do not contain the same number of thyroid
hormone receptors, resulting in a differential sensitivity of
muscle types to the hormone [5]. Taken together these
results suggest that T3 influences the skeletal muscles
sphingolipids profile in a fiber specific manner. However,
one can question that increased ceramide metabolism is
solely due to direct T3 actions in skeletal muscles since,
in vivo, key enzymes involved in sphingolipid metabolism
are regulated by many physiological and environmental
stimuli [11]. It is therefore possible, that T3 induced
changes in ceramide metabolism are secondary, and are
due to the increased availability of serum fatty acids,
provoked by triiodothyronine-induced adipose tissue
lipolysis. Probably, this may be the case in our study, since
we observed increased serum FFA followed by greater
activity of serine palmitoyltransferase (a key enzyme
responsible for de novo generation of ceramide) [33]. It is
well known, that the activity of SPT is directly stimulated
by the presence of long chain fatty acids (e.g. palmitate, a
major representative of serum FFA) [34] and some studies
show that de novo ceramide synthesis can be driven
exclusively by increased availability of fatty acids [35, 36].
Further, indirect evidence, for increased de novo ceramide
generation can be drawn from our observations of the
greater content in sphinganine than sphingosine, especially
since sphinganine is considered to be a key intermediate
substrate in the de novo ceramide synthesis pathway and
sphingosine is one of the major ceramide degradation
products [8]. It is probable that the sphingolipid changes
were closely related to increased activity of either SPT-1
and ceramidases (neutral and alkaline CDase), but inter-
estingly the activity of sphingosine kinase (SPHK) must
have remained quite stable, since sphingosine-1 phosphate
levels did not change significantly. Beyond this correlation,
several studies have provided evidence for relatively low
expression and activity of SPHK in skeletal muscles [37].
In contrast, it is also plausible that increased activity of
sphingomyelinase may contribute to ceramide accumula-
tion, through the enhanced hydrolysis of sphingomyelin.
Recently increased abundance/activity of either neutral or
acid sphingomyelinase that generated increased ceramide
levels, has been reported in the adipose tissue of ob/ob and
high fat diet induced obese mice [38] and rats [39], but in
the present study we did not observe significant T3-induced
changes in the activity of sphingomyelinase.
To summarize, we have shown that hyperthyroidism
increases sphingolipid metabolism in skeletal muscles in a
fiber specific manner, exclusively in more oxidative mus-
cles. T3 induced accumulation of ceramide in more oxi-
dative muscles was further related to de novo synthesis
rather than to the hydrolysis of sphingomyelin.
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